HSBC sees steady growth for India healthcare; raise TP on Dr. Reddy's
** HSBC maintains "buy" and raises TP to 1,525 rupees from 1,375 rupees on Dr. Reddy's Laboratories REDY.NS, citing better pricing for semaglutide and stronger growth for India formulations
** Rates "buy" on Apollo Hospitals APLH.NS, Aster DM ATRD.NS, Torrent Pharmaceuticals TORP.NS and Glenmark Pharmaceuticals GLEN.NS, citing stronger earnings visibility
** Brokerage notes that Q2FY27 healthcare earnings were largely in-line, driven by healthy trends in India formulation business and key launches in the U.S.
** Says outlook for health care looks intact despite concerns from trade margin cap on Oncology drugs
** Notes limited impact from higher input and logistics costs due to the Middle East situation; remains watchful